Alberta Investment Management Corp Increases Stock Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

Alberta Investment Management Corp raised its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 15.3% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 4,447 shares of the company’s stock after buying an additional 589 shares during the quarter. Alberta Investment Management Corp’s holdings in Medpace were worth $1,477,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the business. Kestra Investment Management LLC raised its holdings in shares of Medpace by 58.3% during the fourth quarter. Kestra Investment Management LLC now owns 1,105 shares of the company’s stock worth $367,000 after purchasing an additional 407 shares during the last quarter. Venturi Wealth Management LLC raised its stake in shares of Medpace by 602.0% during the 4th quarter. Venturi Wealth Management LLC now owns 344 shares of the company’s stock valued at $114,000 after buying an additional 295 shares during the last quarter. Truist Financial Corp lifted its holdings in shares of Medpace by 166.2% in the 4th quarter. Truist Financial Corp now owns 10,277 shares of the company’s stock valued at $3,414,000 after buying an additional 6,417 shares during the period. CIBC Asset Management Inc lifted its holdings in shares of Medpace by 5.3% in the 4th quarter. CIBC Asset Management Inc now owns 936 shares of the company’s stock valued at $311,000 after buying an additional 47 shares during the period. Finally, Sanctuary Advisors LLC boosted its stake in shares of Medpace by 20.5% in the fourth quarter. Sanctuary Advisors LLC now owns 4,964 shares of the company’s stock worth $1,738,000 after buying an additional 844 shares during the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Analysts Set New Price Targets

Separately, Robert W. Baird boosted their price target on Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a report on Monday, January 27th. Seven analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, Medpace currently has an average rating of “Hold” and a consensus price target of $381.44.

Medpace Trading Down 1.2 %

Shares of MEDP opened at $340.78 on Friday. The firm has a market cap of $10.38 billion, a P/E ratio of 26.98, a PEG ratio of 3.80 and a beta of 1.36. Medpace Holdings, Inc. has a 12 month low of $302.01 and a 12 month high of $459.77. The stock’s 50 day moving average is $343.23 and its two-hundred day moving average is $347.46.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. Equities research analysts forecast that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.